AKBA - Company ID 0001517022
The table below shows Akebia Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $49.13M | $53.54M | $58.77M | $62.47M | $57.34M | $37.43M |
| Cost of revenue | $10.42M | $12.29M | $9.38M | $9.92M | $7.63M | $14.16M |
| Gross profit | - | - | - | - | - | - |
| R&D | $14.06M | $14.81M | $14.94M | $11.01M | $9.75M | $8.49M |
Akebia Therapeutics, Inc. reported annual revenue of $236.20M for fiscal year 2025. That is up 47.5% from $160.18M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.53M (FY 2016) to $236.20M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $28.17M |
| $30.44M |
| $29.09M |
| $26.55M |
| $25.74M |
| $26.52M |
| Operating income | -$6.33M | -$4.70M | $4.45M | $14.09M | $13.51M | -$12.51M |
| Income tax | $70.00K | $126.00K | $615.00K | $0.00 | $0.00 | $0.00 |
| Net income | -$8.91M | -$9.05M | $540.00K | $247.00K | $6.11M | -$20.04M |
| EPS (diluted) | -$0.03 | -$0.03 | $0.00 | $0.00 | $0.03 | -$0.10 |